NCT00416091 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Barkley RA (1997), Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD
Psychol Bull 121: 65-94 Channon S, Pratt P, Robertson MM (2003b), Executive function, memory, and learning in Tourette's disorder. Neuropsychology 17: 247-54 Gau SS, Soong WT, Chiu YN, Tsai WC (2006a), Psychometric properties of the Chinese version of the Conners' Teacher and Parent Rating Scales-Revised Short Form. Journal of Attention Disorders. 9: 648-659 Gau SSF, Shen HY, Soong WT, Gau CS (2006b), An open-label, randomized, active controlled equivalent trial of OROS methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology 16 (in press) Kurlan R, Whitmore D, Irvine C, McDermott MP, Como PG (1994), Tourette's disorder in a special education population: a pilot study involving a single school district. Neurology 44: 699-702

Neuropsychological Functioning, Symptomatology, and Social Adjustment Among Children With Tourret's Disorder, Attention-Deficit/Hyperactivity Disorder, and Comorbid Conditions.

Details for clinical trial NCT00416091

Clinical trial NCT00416091 - References